Shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) dropped 4.1% during trading on Thursday . The company traded as low as $160.40 and last traded at $165.51, with a volume of 383,901 shares traded. The stock had previously closed at $172.59.

ICPT has been the topic of a number of research reports. Vetr raised shares of Intercept Pharmaceuticals from a “sell” rating to a “hold” rating and set a $147.31 price objective on the stock in a research report on Monday, April 11th. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Wednesday, June 1st. Goldman Sachs Group Inc. upped their price target on shares of Intercept Pharmaceuticals from $114.00 to $128.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 31st. Morgan Stanley reaffirmed a “sell” rating on shares of Intercept Pharmaceuticals in a research report on Saturday, April 9th. Finally, Robert W. Baird reaffirmed an “outperform” rating and set a $332.00 price target on shares of Intercept Pharmaceuticals in a research report on Wednesday, June 1st. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Intercept Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $187.98.

The stock has a 50 day moving average price of $151.26 and a 200 day moving average price of $136.16. The stock’s market cap is $4.01 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($3.14) earnings per share for the quarter, beating the consensus estimate of ($3.69) by $0.55. The company had revenue of $5.52 million for the quarter, compared to the consensus estimate of $1.72 million. During the same quarter last year, the business posted ($1.99) earnings per share. Intercept Pharmaceuticals’s revenue was up 1140.4% on a year-over-year basis. Analysts predict that Intercept Pharmaceuticals Inc. will post ($17.01) EPS for the current fiscal year.

In other Intercept Pharmaceuticals news, CEO Mark Pruzanski sold 714 shares of the firm’s stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $145.11, for a total transaction of $103,608.54. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Lisa Bright sold 251 shares of the firm’s stock in a transaction on Wednesday, May 25th. The shares were sold at an average price of $137.50, for a total value of $34,512.50. Following the transaction, the insider now owns 18,855 shares in the company, valued at $2,592,562.50. The disclosure for this sale can be found here.

Several large investors have added to or reduced their stakes in ICPT. BlackRock Advisors LLC boosted its stake in Intercept Pharmaceuticals by 5.4% in the fourth quarter. BlackRock Advisors LLC now owns 125,274 shares of the biopharmaceutical company’s stock worth $18,710,000 after buying an additional 6,461 shares during the last quarter. New York State Common Retirement Fund boosted its stake in Intercept Pharmaceuticals by 2.2% in the fourth quarter. New York State Common Retirement Fund now owns 37,400 shares of the biopharmaceutical company’s stock worth $5,586,000 after buying an additional 800 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Intercept Pharmaceuticals by 1.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 36,610 shares of the biopharmaceutical company’s stock worth $5,468,000 after buying an additional 578 shares during the last quarter. Finally, Rhumbline Advisers boosted its stake in Intercept Pharmaceuticals by 0.7% in the fourth quarter. Rhumbline Advisers now owns 15,849 shares of the biopharmaceutical company’s stock worth $2,367,000 after buying an additional 109 shares during the last quarter.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.